Literature DB >> 16401380

Appropriate invasive and conservative treatment approaches for patients with non-ST-elevation MI.

Benjamin M Scirica1, David A Morrow.   

Abstract

Compelling evidence from randomized clinical trials has established the superiority of an early invasive over a conservative management strategy in patients presenting with non-ST-segment acute coronary syndromes, with a 20% to 40% reduction in recurrent ischemic events in patients undergoing routine early angiography and revascularization when appropriate. Those patients at high risk of death, recurrent myocardial infarction, or ischemia as indicated by elevated concentrations of cardiac troponin, ST-segment deviation, or high clinical risk score derive a greater clinical benefit from early invasive management than patients at lower risk who may be managed effectively with either strategy. Patients who have recurrent ischemia, infarction, hemodynamic instability, or a high-risk stress test should be considered for urgent catheterization regardless of the initial strategy chosen.

Entities:  

Year:  2006        PMID: 16401380     DOI: 10.1007/s11936-006-0022-x

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  25 in total

1.  5-year outcome of an interventional strategy in non-ST-elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised trial.

Authors:  K A A Fox; P Poole-Wilson; T C Clayton; R A Henderson; T R D Shaw; D J Wheatley; R Knight; S J Pocock
Journal:  Lancet       Date:  2005 Sep 10-16       Impact factor: 79.321

2.  Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.

Authors:  C P Cannon; W S Weintraub; L A Demopoulos; R Vicari; M J Frey; N Lakkis; F J Neumann; D H Robertson; P T DeLucca; P M DiBattiste; C M Gibson; E Braunwald
Journal:  N Engl J Med       Date:  2001-06-21       Impact factor: 91.245

3.  Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials.

Authors:  Shamir R Mehta; Christopher P Cannon; Keith A A Fox; Lars Wallentin; William E Boden; Rudolf Spacek; Petr Widimsky; Peter A McCullough; David Hunt; Eugene Braunwald; Salim Yusuf
Journal:  JAMA       Date:  2005-06-15       Impact factor: 56.272

4.  Value of first day angiography/angioplasty in evolving Non-ST segment elevation myocardial infarction: an open multicenter randomized trial. The VINO Study.

Authors:  R Spacek; P Widimský; Z Straka; E Jiresová; J Dvorák; R Polásek; I Karel; R Jirmár; L Lisa; T Budesínský; F Málek; P Stanka
Journal:  Eur Heart J       Date:  2002-02       Impact factor: 29.983

5.  An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS.

Authors:  D A Morrow; E M Antman; S M Snapinn; C H McCabe; P Theroux; E Braunwald
Journal:  Eur Heart J       Date:  2002-02       Impact factor: 29.983

6.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

Authors:  S Yusuf; F Zhao; S R Mehta; S Chrolavicius; G Tognoni; K K Fox
Journal:  N Engl J Med       Date:  2001-08-16       Impact factor: 91.245

7.  Use of risk stratification to identify patients with unstable angina likeliest to benefit from an invasive versus conservative management strategy.

Authors:  D H Solomon; P H Stone; R J Glynn; D A Ganz; C M Gibson; R Tracy; J Avorn
Journal:  J Am Coll Cardiol       Date:  2001-10       Impact factor: 24.094

8.  Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes.

Authors:  E M Antman; M J Tanasijevic; B Thompson; M Schactman; C H McCabe; C P Cannon; G A Fischer; A Y Fung; C Thompson; D Wybenga; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-31       Impact factor: 91.245

9.  Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS).

Authors:  David A Morrow; Marc S Sabatine; Elliott M Antman; Christopher P Cannon; Eugene Braunwald; Pierre Theroux
Journal:  Am J Cardiol       Date:  2004-09-15       Impact factor: 2.778

10.  Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia.

Authors: 
Journal:  Circulation       Date:  1994-04       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.